公开(公告)号：WO2010006059A8

公开(公告)日：2010-09-02

申请号：PCT/US2009049953

申请日：2009-07-08

Applicant: ABBOTT LAB ,  GU JIJIE ,  HUTCHINS CHARLES W ,  ZHU RONG-RONG ,  SHEN JIANWEI ,  HARRIS MARIA C ,  BELANGER EILEEN ,  MURTAZA ANWAR ,  TARCSA EDIT ,  STINE WILLIAM B ,  HSIEH CHUNG-MING

Inventor： GU JIJIE ,  HUTCHINS CHARLES W ,  ZHU RONG-RONG ,  SHEN JIANWEI ,  HARRIS MARIA C ,  BELANGER EILEEN ,  MURTAZA ANWAR ,  TARCSA EDIT ,  STINE WILLIAM B ,  HSIEH CHUNG-MING

IPC: A61K39/395

CPC classification number: C07K16/18 ,  A61K31/405 ,  A61K31/573 ,  A61K39/39533 ,  A61K2039/505 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.

Abstract translation: 本发明包括前列腺素E2（PGE2）结合蛋白。 本发明涉及野生型，嵌合，CDR移植和人源化的抗体。 优选的抗体对前列腺素E2具有高亲和力并且在体外和体内中和前列腺素E2的活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗原结合部分可用于检测前列腺素E2和用于抑制前列腺素E2活性，例如，在患有前列腺素E2活性是有害的病症的人类受试者中。

公开(公告)号：WO2010102251A3

公开(公告)日：2010-11-25

申请号：PCT/US2010026424

申请日：2010-03-05

Applicant: ABBOTT LAB ,  HSIEH CHUNG-MING ,  HUGUNIN MARGARET ,  MURTAZA ANWAR ,  MCRAE BRADFORD L ,  KUTSKOVA YULIYA ,  MEMMOTT JOHN E ,  PEREZ JENNIFER M ,  ZHONG SUJU ,  TARCSA EDIT ,  CLABBERS ANCA ,  WALLACE CRAIG ,  BRYANT SHAUGHN H ,  LEDDY MARY R

Inventor： HSIEH CHUNG-MING ,  HUGUNIN MARGARET ,  MURTAZA ANWAR ,  MCRAE BRADFORD L ,  KUTSKOVA YULIYA ,  MEMMOTT JOHN E ,  PEREZ JENNIFER M ,  ZHONG SUJU ,  TARCSA EDIT ,  CLABBERS ANCA ,  WALLACE CRAIG ,  BRYANT SHAUGHN H ,  LEDDY MARY R

IPC: A61K39/395

CPC classification number: C07K16/468 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2300/00 ,  C07K16/241 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/50 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92

Abstract: Proteins that bind IL- 17 and/or IL- 17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL- 17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

Abstract translation: 描述了结合IL-17和/或IL-17F的蛋白以及其在用于治疗，预防和诊断IL-17相关疾病和检测细胞，组织，样品和组合物中的IL-17的组合物和方法中的应用。

公开(公告)号：EP2403531A4

公开(公告)日：2013-02-27

申请号：EP10749415

申请日：2010-03-05

Applicant: ABBOTT LAB

Inventor： HSIEH CHUNG-MING ,  HUGUNIN MARGARET ,  MURTAZA ANWAR ,  MCRAE BRADFORD L ,  KUTSKOVA YULIYA ,  MEMMOTT JOHN E ,  PEREZ JENNIFER M ,  ZHONG SUJU ,  TARCSA EDIT ,  CLABBERS ANCA ,  WALLACE CRAIG ,  BRYANT SHAUGHN H ,  LEDDY MARY R

IPC: A61K39/395

CPC classification number: C07K16/468 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2300/00 ,  C07K16/241 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/50 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92

Abstract: Proteins capable of binding human IL-17 and TNF-± are described along with their use in composition and methods for treating, preventing, and diagnosing diseases related to IL- 17 and TNF-± related diseases and for detecting and/or TNF-± in cells, tissues, samples, and compositions.

Abstract translation: 描述了结合IL-17和/或IL-17F的蛋白质及其在治疗，预防和诊断IL-17相关疾病和用于检测细胞，组织，样品和组合物中的IL-17的组合物和方法中的用途。

公开(公告)号：CL2013003640A1

公开(公告)日：2014-07-25

申请号：CL2013003640

申请日：2013-12-18

Applicant: ABBOTT LAB

Inventor： HSIEH CHUNG-MING ,  MURTAZA ANWAR ,  MCRAE BRADFORD L ,  KUTSKOVA YULIYA ,  MEMMOTT JOHN E ,  PEREZ JENNIFER M ,  ZHONG SUJU ,  TARCSA EDIT ,  CLABBERS ANCA ,  WALLACE CRAIG ,  BRYANT SHAUGHH H ,  LEDDY MARY R ,  HUGUNIN MARGARET

IPC: C07K16/24 ,  A61K39/395 ,  A61P35/00

公开(公告)号：CA2752648A1

公开(公告)日：2010-09-10

申请号：CA2752648

申请日：2010-03-05

Applicant: ABBOTT LAB

Inventor： HSIEH CHUNG-MING ,  HUGUNIN MARGARET ,  MURTAZA ANWAR ,  MCRAE BRADFORD L ,  KUTSKOVA YULIYA ,  MEMMOTT JOHN E ,  PEREZ JENNIFER M ,  ZHONG SUJU ,  TARCSA EDIT ,  CLABBERS ANCA ,  WALLACE CRAIG ,  BRYANT SHAUGHN H ,  LEDDY MARY R

IPC: A61K39/395

Abstract: Proteins that bind IL- 17 and/or IL- 17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL- 17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

公开(公告)号：SG192496A1

公开(公告)日：2013-08-30

申请号：SG2013052923

申请日：2009-07-08

Applicant: ABBOTT LAB

Inventor： GU JIJIE ,  HUTCHINS CHARLES W ,  ZHU RONG-RONG ,  SHEN JIANWEI ,  HARRIS MARIA C ,  BELANGER EILEEN ,  MURTAZA ANWAR ,  TARCSA EDIT ,  STINE WILLIAM B ,  HSIEH CHUNG-MING

Abstract: PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF AbstractThe present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E, activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.Figure I

公开(公告)号：CO6410314A2

公开(公告)日：2012-03-30

申请号：CO11108934

申请日：2011-08-25

Applicant: ABBOTT LAB

Inventor： HSIEH CHUNG-MING ,  HUGUNING MARGARET ,  LEDDY MARY R ,  BRYANT SHAUGHN ,  WALLACE CRAIG ,  CLABBERS ANCA ,  TARCSA EDIT ,  ZHONG SUJU ,  PEREZ JENNIFER M ,  MEMMOTT JOHN E ,  KUTSKOVA YULIYA ,  MCRAE BRADFORD L ,  MURTAZA ANWAR

IPC: A61K39/395

Abstract: Se describen proteínas que se unen a IL-17 y/o IL-17F junto con su uso en la composición y métodos para el tratamiento, prevención y diagnóstico de enfermedades relacionadas con la IL-17 y para detectar IL-17 en células, tejidos, muestras y composiciones.

公开(公告)号：ECSP11011297A

公开(公告)日：2011-10-31

申请号：ECSP11011297

申请日：2011-09-01

Applicant: ABBOTT LAB

Inventor： LEDDY MARY R ,  HSIEH CHUNGMING ,  MURTAZA ANWAR ,  MCRAE BRADFORD L ,  KUTSKOVA YULIYA ,  MEMMOTT JOHN E ,  PEREZ JENNIFER M ,  ZHONG SUJU ,  TARCSA EDIT ,  CLABBERS ANCA ,  WALLACE CRAIG ,  BRYANT SHAUGHN H

IPC: A61K39/395

Abstract: Proteínas que unen IL-17 y/o IL-7F se describen junto con su uso en composición y métodos para el tratamiento, la prevención y el diagnóstico de enfermedades relacionadas con IL-17 y para la detección de IL-17 en células, tejidos, muestras y composiciones.

公开(公告)号：BRPI1013688A2

公开(公告)日：2016-10-11

申请号：BRPI1013688

申请日：2010-03-05

Applicant: ABBOTT LAB

Inventor： CLABBERS ANCA ,  MURTAZA ANWAR ,  MCRAE BRADFORD L ,  HSIEH CHUNG-MING ,  WALLACE CRAIG ,  TARCSA EDIT ,  PEREZ JENNIFER M ,  MEMMOTT JOHN E ,  HUGUNIN MARGARET ,  LEDDY MARY R ,  BRYANT SHAUGHN H ,  ZHONG SUJU ,  KUTSKOVA YULIYA

IPC: A61K39/395

公开(公告)号：CA2728909A1

公开(公告)日：2010-01-14

申请号：CA2728909

申请日：2009-07-08

Applicant: ABBOTT LAB

Inventor： GU JIJIE ,  HUTCHINS CHARLES W ,  ZHU RONG-RONG ,  SHEN JIANWEI ,  HARRIS MARIA C ,  BELANGER EILEEN ,  MURTAZA ANWAR ,  TARCSA EDIT ,  STINE WILLIAM B ,  HSIEH CHUNG-MING

IPC: C07K16/18 ,  A61K39/395 ,  C07K16/46 ,  C12N15/13

Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.